ClinicalTrials.gg
Not yet recruitingNCT07850635Updated Oct 21, 2026

A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

A Phase 1 interventional study of Mirdametinib in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas, sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. Not yet recruiting at 1 site in Germany. Open to participants aged 0 Months to 21 Months. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Treatment

Updated Oct 21, 2026Start date movedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
0 Months to 21 Months
Sex
All
01

Study summary

The purpose of this study is to determine the safety, pharmacokinetic (PK), and tolerability of multiple treatment cycles of oral mirdametinib in infants and toddlers (0 to less than [\<] 24 months of age) with measurable neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PNs) that is symptomatic or asymptomatic but in a high-risk location with a high risk of morbidity.

02

Conditions studied

  • Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Keywords

  • Mirdametinib
  • Single arm study
03

In context

Neurofibroma, Plexiform

63 studies on the registry are indexed under Neurofibroma, Plexiform; 19 are open to participants now.

This study's planned enrollment of 6 is below the median of 36 across 43 interventional studies indexed under Neurofibroma, Plexiform.

Browse Neurofibroma, Plexiform studies →

Lead sponsor

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.

First submitted after SpringWorks Therapeutics, Inc. became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Months to 21 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 1.1 Cohort 1: greater than (>) 12 to less than or equal to (\<=) 21 months of age at first dose 1.2 Cohort 2: 0 to \<=9 months of age at first dose For both cohorts, corrected age must be used to determine eligibility for age at first dose. Note: Corrected age is the age of the infant from the expected date of delivery (40 weeks gestation), rather than from the actual date of birth. For example, a 3-month-old infant who was born 2 months early would have a corrected age of 1 month.
  2. Participants must have had the clinical diagnosis of NF1 according to the 2021 International Consensus Guidelines with presence of a PN and at least 1 additional diagnostic criterion for NF1.
  3. Participants must have a target PN, defined as the clinically most relevant PN amenable to volumetric MRI analysis. For the purpose of this study, the target PN must be seen on at least 3 consecutive MRI slices and the field of view must contain the entire tumour of interest. As determined by central radiologic review, a target PN must be analysable by volumetrics using Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS), at least 3 milliliter (mL) in volume.
  4. Participants must have 1 of the following presentations of PN:

4.1. Asymptomatic: Participant has a measurable NF1 PN in a high risk location with a high risk of morbidity.

A high-risk location with a high risk of morbidity is defined as:

  • In the head or neck (except for isolated scalp lesions) OR
  • Within the brachial or lumbosacral plexus OR
  • Adjacent to high-risk structure(s), defined as:

    • Major ("named") blood vessel OR
    • Major ("named") airway OR
    • Hollow viscus OR
    • Spinal cord and foramina OR
    • Vital organs (including heart, lungs, liver, spleen, etc) OR 4.2. Symptomatic: Participant has a PN that is causing clinical symptoms at the discretion of the investigator (e.g., head and neck lesions compromising the airway or great vessels, brachial or lumbar plexus lesions causing nerve compression and loss of function, lesions causing major deformity or significant disfigurement, lesions of the extremity causing limb hypertrophy or loss of function, and painful lesions).

Exclusion criteria

Exclusion Criteria:

  1. Participant has family history of sudden cardiac death.
  2. Participant has a history of, or evidence of, retinal pathology on ophthalmologic examination that is considered a risk factor for central serous retinopathy, retinal vein occlusion (RVO), retinal pigment epithelial detachment, or neovascular macular degeneration.
  3. Participant has a history of congenital glaucoma.
  4. Participant has received NF1 PN-targeted therapy (e.g., farnesyltransferase inhibitors, kinase inhibitors, etc) within 28 days of first dose of study treatment (or 5 half-lives, whichever is longer). All toxicities from prior therapy must resolve to Grade \<=1 or baseline.
  5. Participant is receiving inhibitors or inducers of P-glycoprotein or breast cancer resistance protein.
  6. Participant is currently enrolled or has past participation in any other clinical study (excluding observational studies) within 28 days of signing of .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Cohort 1: 12 to 21 months of age

    Participant receives 0.5 milligram (mg) twice daily.

    Drug: Mirdametinib

  • Experimental
    Cohort 2: 0 to 9 months of age

    Participants receives 0.25 mg twice daily.

    Drug: Mirdametinib

Interventions

  • Mirdametinib dispersible tablet administered orally.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 6 years

  2. Number of Participants With Clinically Significant Changes in Laboratory Parameters, Vital Signs, Physical Examination Findings and Electrocardiograms (ECGs), Echocardiogram (ECHO), and Ophthalmic Exam Findings

    Time frame: Up to approximately 6 years

  3. Number of Participants With Severity of Adverse Events (AEs) According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0

    Time frame: Up to approximately 6 years

  4. Minimum Observed Concentration (Cmin) of Mirdametinib

    Time frame: Cycle 1 Days 1 and 15: pre-dose and post-dose at 1 and 4 hours; Cycles 2, 4 and 8 Day 15: Pre-dose and post-dose at 1 hour (each cycle = 28 days)

  5. Maximum Observed Concentration (Cmax) of Mirdametinib

    Time frame: Cycle 1 Days 1 and 15: pre-dose and post-dose at 1 and 4 hours; Cycles 2, 4 and 8 Day 15: Pre-dose and post-dose at 1 hour (each cycle = 28 days)

  6. Area Under the Concentration-time Curve (AUC) at Steady State for Mirdametinib

    Time frame: Cycle 1 Days 1 and 15: pre-dose and post-dose at 1 and 4 hours; Cycles 2, 4 and 8 Day 15: Pre-dose and post-dose at 1 hour (each cycle = 28 days)

Secondary outcomes

  1. Confirmed Objective Response Rate (ORR)

    Confirmed ORR is defined as plexiform neurofibroma (PN) decrease greater than or equal to (\>=) 20 percent (%) compared to baseline in consecutive scans within 2 to 6 months) using centrally read magnetic resonance imaging (MRI) volumetric analyses by a Blinded Independent Central Review (BICR).

    Time frame: Up to approximately 6 years

  2. Duration of Response (DoR)

    DoR is defined as the time from onset of confirmed complete response (CR) + partial response (PR) using centrally read MRI volumetric analysis by a BICR to the earliest event of progressive disease (PD) or death.

    Time frame: Up to approximately 6 years

  3. Change From Baseline in Quality of Life (QoL) Assessed by the age-specific Pediatric Quality of Life Inventory (PedsQL) Infant Scales

    The PedsQL Infant Scales are multidimensional parent-proxy-report scales designed to assess health-related quality of life in infants from 1 to 24 months of age over the past 7 days. The Infant Scales consists of 36 items in the 1- to 12-month form and 45 items in the 13- to 24-month form, with 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.

    Time frame: Baseline up to approximately 6 years

  4. Change From Baseline Pain Assessment by Age-specific Pain Scale: Faces, Legs, Activity, Cry, Consolability (FLACC)

    FLACC is a behavioural pain assessment scale used by the investigator for nonverbal or preverbal patients who are unable to self-report their level of pain. Pain is assessed in infants and children from 2 months to 7 years of age through observation of 5 categories, including face, legs, activity, cry, and consolability. The total score for FLACC scale ranges from 0 to 10, with each category scored on a scale of 0 to 2.

    Time frame: Baseline up to approximately 6 years

07

Study locations

1 site
  • Research Site
    Darmstadt, Germany
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared for Phase I interventional or observational studies. Further information on how to request data can be found on our website bit.ly/IPD21.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Oct 2032, 70 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Sep 30, 2026
StartEst.
Dec 9, 2026
Primary completionEst.
Oct 21, 2032
CompletionEst.
Oct 21, 2032
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 10, 2026→Dec 9, 2026
Oct 21, 2026
Registered
First appeared on the registry
Sep 30, 2026
Show all 2 updates
  1. Oct 21, 2026
    Start date Dec 10, 2026→Dec 9, 2026
    + 1 other change: verification date
  2. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07850635
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Dec 9, 2026 (estimated)
Primary completion
Oct 21, 2032 (estimated)
Completion
Oct 21, 2032 (estimated)
Last update
Oct 21, 2026

Study contacts

Communication Center
Contact
service@emdgroup.com
+49 6151 72 5200
Medical Responsible
study director · SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirdametinib

Start the discussion